The EU Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing...
Domp� announced the acceptance of the registration application submitted to the European Medicines Agency (EMA) for Oxervate eye drops, for...
The National Institute for Health and Care Excellence has published draft guidelines rejecting funding for Oxervate (cenegermin) from Dompé
Domp� has announced that the FDA has approved Oxervate (cenegermin), a breakthrough therapy for neurotrophic keratitis (NK), a rare and...